As the initiating country and a major funder for JPIAMR, III staff has a place on the Management Board as well as Call Steering Group and has provided input to the call text as well as the generation of an MOU and design of the application and peer review processes. CIHR has previous experience of collaboration on other JPI and ERA-NET programs.
CIHR has made substantial investments in discovery research focused on antibiotic resistance and III has supported several targeted initiatives in the areas of drug development, alternative therapies, combination approaches and infection control. Canada’s interest in JPIAMR stems from a desire to combine the resources, infrastructures, and expertise of many countries to provide a value-added, collaborative approach that will fast track the development of effective solutions to antimicrrobial resistance.
Canada, through CIHR-III, has also lead the development a JPIAMR Virtual Research Institute (JPIAMR-VRI), which will provide a platform to increase coordination, improve visibility of the AMR researcher base and facilitate knowledge exchange and capacity development across the globe, covering the full One Health spectrum.
Established in 2000, CIHR is the Government of Canada’s premier health research funding agency, promoting a problem-based, multidisciplinary and collaborative approach to health research. CIHR supports health research in four broad areas: biomedical; clinical; health systems and services; and the social, cultural and environmental factors that affect the health of populations. The mandate of CIHR is “to excel, according to internationally accepted standards of scientific excellence, in the creation of new knowledge, and its translation into improved health for Canadians, more effective health services and products and a strengthened Canadian health care system”.
The Institute of Infection and Immunity is one of the thirteen virtual institutes of the Canadian Institutes of Health Research. The Institute is located at the University of Laval in Quebec City under the leadership of the current Scientific Director, Dr. Marc Ouellette. III has a mandate to support research to enhance immune-mediated health and to reduce the burden of infectious disease, immune-mediated disease and allergy through prevention strategies, screening, diagnosis, treatment, support systems and palliation. The III mandate transcends disciplines and encompasses all four health research themes: biomedical; clinical; health systems and services; and social, cultural and environmental factors that affect the health of populations.
CIHR has made substantial investments in discovery research focused on antibiotic resistance and III has supported several targeted initiatives in the areas of drug development, alternative therapies, combination approaches and infection control. Canada’s interest in JPIAMR stems from a desire to combine the resources, infrastructures, and expertise of many countries to provide a value-added, collaborative approach that will fast track the development of effective solutions to antibiotic resistance.
National AMR research program and activities
National AMR Research Calls
- JPIAMR Transnational Call 2020 – JPIAMR Network Plus
- JPIAMR Transnational Call 2019 – Diagnostic & Surveillance call Transmission Dynamics
- Network for Global Governance Research on Infectious Diseases 2019
- JPIAMR Network Call 2018 – “Building the foundation of the JPIAMR-Virtual Research Institute”
- AMR Point of Care Diagnostics Phase II 2018 – supports the development, evaluation, or implementation of point-of-care diagnostic tools.
- JPIAMR Prevention and Control 2017 – “Prevention and Intervention Strategies to Control AMR Infections
Activities on AMR at national level
Between 2014-15 and 2018-19, CIHR invested over $125 million to strengthen AMR research in areas such as antimicrobial discovery, target identification, alternatives, diagnostics, surveillance and stewardship. Additionally, the Genomics Research and Development Initiative AMR project (GRDI-AMR), which receives close to $20M annually from the Government of Canada to carry out vital genomics research, launched the AMR project (2016-2021) with a total GRDI funding of over $9M. This project uses genomics-based approach to understand how food production contributes to the development of AMR of human health concern, and to explore strategies for reducing AMR in food production systems.
In June 2020, Canada published the Canadian Antimicrobial Resistance Surveillance System (CARSS) Report which provides a detailed assessment of antimicrobial resistance (AMR) in Canada. This report also provides recent information on the amount of antimicrobials used in humans and animals, as antimicrobial use (AMU) is one of the key drivers of AMR.
In November 2019, the Council of Canadian Academies (CCA) issued the report “When Antibiotics Fail” which examines the current and future impact of antimicrobial resistance (AMR) on the health and wealth of Canada, and looks at how widespread resistance will influence the day-to-day lives of Canadians and explores promising strategies to mitigate the issue. The report presents new health and economic data for Canada through a One Health lens, recognizing the interconnected nature of AMR, from healthcare settings to the environment to the agriculture sector. It is the most comprehensive assessment of this global threat in the Canadian context.
National action plans
- Antimicrobial Resistance and Use in Canada: A Federal Framework for Action (2014)
- Federal Action Plan on AMR and Use in Canada (2015)
- Development of the Pan-Canadian Action Plan on AMR (ongoing)
Management Board representatives
- Charu Kaushic, CIHR Institute of Infection and Immunity
- Édith Brochu, CIHR Institute of Infection and Immunity